Rayville

Researchers are evaluating the effectiveness and safety of NeoThelium FT Amnion Skin Graft for treating chronic pressure ulcers in this prospective case series. The study is conducted at multiple medical centers where both doctors and patients know which treatment is being used. This post-marketing study aims to collect data to support insurance reimbursement decisions while assessing the treatment’s efficacy. Participants will receive standard care plus weekly applications of NeoThelium FT, a dehydrated wound covering made from human placental tissue with dual amnion and chorion layers. Treatment continues according to a set schedule, with ongoing follow-up visits. NeoThelium FT is applied to pressure ulcers located on the pelvis or lower extremities. Throughout the study, patients will be monitored regularly to assess wound healing and safety. The main outcome measured is complete wound closure within 1 to 16 weeks. Researchers will perform assessments including checks for infection, ulcer size and depth, circulation status, and adherence to offloading therapy. Participants will continue follow-up as planned to track treatment progress and outcomes.